Functioning and nonfunctioning neuroendocrine tumors of the pancreas

被引:55
作者
Dixon, Elijah
Pasieka, Janice L.
机构
[1] Univ Calgary, Dept Surg & Oncol, Calgary, AB T2N 2T9, Canada
[2] Tom Baker Canc Clin, Calgary, AB T2N 2T9, Canada
关键词
islet cell tumors; neuroendocrine tumor;
D O I
10.1097/CCO.0b013e328011a236
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review Neuroendocrine tumors of the pancreas are a small subgroup of tumors characterized by a variety of biological behaviors. Recent changes in their classification should help better define the prognosis of this diverse group of tumors. With recent advances in diagnosis and staging, the treatment options for all neuroendocrine tumors have evolved. Presented here is a review,of the current-day knowledge for neuroendocrine tumors of the pancreas. Recent findings A consensus by leading experts in the neurendocrine tumors field has proposed an algorithm for the diagnosis, treatment and follow-up of these rare tumors. Surgical resection remains the first-line therapy. Alternative forms (if cytoreduction such as radiofrequency ablation,ana embolization, have increased the ability of the surgeon to debulk these tumors, resulting in improved survival and better palliation. Contrary to adenocarcinoma of the pancreas, hormonal and biotherapy offer unique treatment strategies for these rare tumors. Very recent developments utilizing radionuclide therapy hold promise for not only palliation, but may prove to be a beneficial form of adjuvant therapy. Summary Presented here is a summary of the recent literature on the diagnosis and treatment of neuroendocrine tumors of the pancreas.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 45 条
  • [1] ALTIMARI AF, 1987, SURGERY, V102, P1009
  • [2] Chemotherapy
    Arnold, R
    Rinke, A
    Schmidt, C
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2005, 19 (04) : 649 - 656
  • [3] Introduction: Definition, historical aspects, classification, staging, prognosis and therapeutic options
    Arnold, R
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2005, 19 (04) : 491 - 505
  • [4] Buscombe JR, 2003, J NUCL MED, V44, P1
  • [5] Hepatic neuroendocrine metastases: Does intervention alter outcomes?
    Chamberlain, RS
    Canes, D
    Brown, KT
    Saltz, L
    Jarnagin, W
    Fong, YM
    Blumgart, LH
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 190 (04) : 432 - 445
  • [6] A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
    Chung, DC
    Smith, AP
    Louis, DN
    GraemeCook, F
    Warshaw, AL
    Arnold, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) : 404 - 410
  • [7] Clark Orlo H, 2006, J Natl Compr Canc Netw, V4, P102
  • [8] de Jong M, 2005, J NUCL MED, V46, p13S
  • [9] 50-year appraisal of gastrinoma: Recommendations for staging and treatment
    Ellison, EC
    Sparks, J
    Verducci, JS
    Johnson, JA
    Muscarella, P
    Bloomston, M
    Melvin, WS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 202 (06) : 897 - 905
  • [10] Developments in PET for the detection of endocrine tumours
    Eriksson, B
    Örlefors, H
    Öberg, K
    Sundin, A
    Bergström, M
    Långström, B
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 19 (02) : 311 - 324